PUBLISHER: DelveInsight | PRODUCT CODE: 1340021
PUBLISHER: DelveInsight | PRODUCT CODE: 1340021
DelveInsight's "Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The chronic rhinosinusitis without nasal polyps market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM chronic rhinosinusitis without nasal polyps market size from 2019 to 2032. The report also covers current chronic rhinosinusitis without nasal polyps treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a prevalent and chronic medical condition characterized by inflammation and swelling of the nasal passages and paranasal sinuses, but notably, it does not involve the presence of nasal polyps.
Individuals with chronic rhinosinusitis without nasal polyps often experience symptoms such as nasal congestion, difficulty breathing through the nose, facial pain or pressure, reduced sense of smell (hyposmia), and a persistent discharge from the nose. These symptoms typically last more than 12 weeks, making it a chronic condition requiring proper management.
Diagnosing chronic rhinosinusitis without nasal polyps involves a thorough examination of the nasal passages and sinuses by medical professionals, who may also consider the patient's medical history and the duration of symptoms to differentiate it from other similar conditions. The diagnosis is typically based on specific diagnostic criteria established by medical guidelines. These criteria include two or more of the following major symptoms: nasal blockage/congestion, nasal discharge, facial pain/pressure, and reduced sense of smell. The symptoms of CRSsNP must be present for at least 12 consecutive weeks to meet the diagnosis. In some cases, the doctor may order imaging studies, such as a CT scan of the sinuses.
Further details related to country-based variations are provided in the report.
Treatment for chronic rhinosinusitis without nasal polyps alleviates inflammation and effectively manages symptoms. Medical management may include the use of nasal corticosteroids to reduce inflammation and antibiotics if there is evidence of a bacterial infection. Nasal irrigations or rinses with saline solutions may also be recommended to help improve nasal health and provide relief. If medical treatment fails to provide sufficient symptom relief or disease control, surgical interventions such as endoscopic sinus surgery (ESS) may be considered.
As the market is derived using the patient-based model, the chronic rhinosinusitis without nasal polyps epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), and Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of chronic rhinosinusitis without nasal polyps in the 7MM was approximately 17 million cases in 2022 and are projected to increase during the forecast period.
The drug chapter segment of the chronic rhinosinusitis without nasal polyps report encloses a detailed analysis of chronic rhinosinusitis without nasal polyps marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands chronic rhinosinusitis without nasal polyps clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Optinose US Inc.'s first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 µg, is therapeutic, utilizing a proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and if approved, chronic rhinosinusitis without nasal polyps. In September 2017, the US FDA approved XHANCE for treating nasal polyps in patients aged 18 or older, and it was made widely available through commercial channels in April 2018. This product candidate is currently in Phase III of its clinical development for CRSsNP.
LYR-210 is an anti-inflammatory implantable drug matrix designed to consistently and locally elute mometasone furoate, or MF, to the inflamed mucosal tissue for up to 6 months in surgically naive CRS patients with and without nasal polyps who have failed previous medical management. LYR-210 is undergoing a Phase III program, the ENLIGHTEN, comprising two pivotal trials. These trials are currently in progress and are crucial in determining the drug's efficacy and safety. Both trials will enroll surgically naive CRS patients in the US and Europe to support the company's FDA submission.
Note: Detailed emerging therapies assessment will be provided in the final report of CRSsNP.
Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient's quality of life.
Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP.
The market for chronic rhinosinusitis without nasal polyps is expected to experience positive growth with the approval of potential drugs like LYR-210, OPN-375/ XHANCE, and LYR-220.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, LYR-210 in the US is expected to have medium-fast drug uptake with a probability-adjusted peak share of around 12%, and years to the peak is expected to be 6 years from the year of launch.
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for chronic rhinosinusitis without nasal polyps emerging therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on chronic rhinosinusitis without nasal polyps evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Surgery, Ralph H. Johnson VA Medical Center; Department of Otorhinolaryngology, Ulm University Medical Center, Frauensteige; Department of Allergy and Medical Rhinology, University College London, London; Department of Pediatrics, Nippon Medical School, Tokyo, and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or chronic rhinosinusitis without nasal polyps market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.